{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:24:12Z","timestamp":1784543052475,"version":"3.55.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.advms.2022.12.003","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T18:11:51Z","timestamp":1673547111000},"page":"54-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genotype 4 hepatitis C virus-a review of a diverse genotype"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-9230","authenticated-orcid":false,"given":"Micha\u0142","family":"Brzd\u0119k","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-9893","authenticated-orcid":false,"given":"Krystyna","family":"Dobrowolska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-1635","authenticated-orcid":false,"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-1084","authenticated-orcid":false,"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2022.12.003_bib1","series-title":"ICTV. Family: Flaviviridae. [Internet]","year":"2017"},{"key":"10.1016\/j.advms.2022.12.003_bib2","series-title":"Hepatitis C [Internet]","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.advms.2022.12.003_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0002-9343(99)00375-7","article-title":"Discovery of non-A, non-B hepatitis and identification of its etiology","volume":"107","author":"Alter","year":"1999","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1016\/j.advms.2022.12.003_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1478-3231.2008.01925.x","article-title":"Discovery of the hepatitis C virus","volume":"29","author":"Houghton","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.advms.2022.12.003_bib5","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5114\/ceh.2016.63870","article-title":"Efficacy of HCV treatment in Poland at the turn of the interferon era \u2013 the EpiTer study","volume":"4","author":"Flisiak","year":"2016","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.advms.2022.12.003_bib9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2014.12.031","article-title":"Efficacy and safety of simeprevir with PegIFN\/ribavirin in na\u00efve or experienced patients infected with chronic HCV genotype 4","volume":"62","author":"Moreno","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3851\/IMP2985","article-title":"Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)","volume":"21","author":"H\u00e9zode","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.advms.2022.12.003_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/0976-500X.142464","article-title":"Sofosbuvir: a novel treatment option for chronic hepatitis C infection","volume":"5","author":"Bhatia","year":"2014","journal-title":"J\u00a0Pharmacol Pharmacother"},{"key":"10.1016\/j.advms.2022.12.003_bib12","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.3390\/cancers13153694","article-title":"Five-year follow-up of cured HCV patients under real-world interferon-free therapy","volume":"13","author":"Flisiak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.advms.2022.12.003_bib13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2893.2006.00823.x","article-title":"Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection","volume":"14","author":"Roulot","year":"2007","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.advms.2022.12.003_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","article-title":"Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial","volume":"4","author":"Gupta","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.advms.2022.12.003_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/hep.22127","article-title":"Hepatitis C genotype 4: what we know and what we don't yet know","volume":"47","author":"Kamal","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/molbev\/msg043","article-title":"The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach","volume":"20","author":"Pybus","year":"2003","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.advms.2022.12.003_bib17","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/jmv.24573","article-title":"Literature review of the distribution of hepatitis C virus genotypes across Europe","volume":"88","author":"Alberti","year":"2016","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.advms.2022.12.003_bib18","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/jmv.20706","article-title":"High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses","volume":"78","author":"Fern\u00e1ndez-Arc\u00e1s","year":"2006","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.advms.2022.12.003_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.virusres.2006.09.001","article-title":"Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1","volume":"123","author":"Franco","year":"2007","journal-title":"Virus Res"},{"key":"10.1016\/j.advms.2022.12.003_bib20","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1128\/JCM.01146-09","article-title":"Emergence of Hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles","volume":"47","author":"de Bruijne","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.advms.2022.12.003_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jmv.21107","article-title":"High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in North-Eastern Poland","volume":"80","author":"Chlabicz","year":"2008","journal-title":"J\u00a0Med Virol"},{"issue":"11\u20136","key":"10.1016\/j.advms.2022.12.003_bib22","first-page":"99","article-title":"Distribution of HCV genotypes in Poland","volume":"67","author":"Panasiuk","year":"2013","journal-title":"Przegl Epidemiol"},{"key":"10.1016\/j.advms.2022.12.003_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5114\/ceh.2016.63871","article-title":"Prevalence of HCV genotypes in Poland \u2013 the EpiTer study","volume":"4","author":"Flisiak","year":"2016","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1099\/vir.0.80409-0","article-title":"Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France","volume":"86","author":"Nicot","year":"2005","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.advms.2022.12.003_bib26","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1053\/j.gastro.2006.03.014","article-title":"Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data","volume":"130","author":"Leandro","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2022.12.003_bib27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/hep.21117","article-title":"Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis","volume":"43","author":"Kamal","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/jir.2016.0111","article-title":"Prediction of fibrosis progression rate in patients with chronic hepatitis C genotype 4: role of cirrhosis risk score and host factors","volume":"37","author":"Besheer","year":"2017","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.advms.2022.12.003_bib29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.52.7.1035","article-title":"Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients","volume":"52","author":"Mohsen","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.advms.2022.12.003_bib30","first-page":"389","article-title":"Pangenotypic and genotype-specific antivirals in the treatment of HCV genotype 4 infected patients with HCV monoinfection and HIV\/HCV coinfection","volume":"11","author":"Zar\u0119bska-Michaluk","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.advms.2022.12.003_bib31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1572-0241.2006.01025.x","article-title":"Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors","volume":"102","author":"Tsochatzis","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.advms.2022.12.003_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0b013e3181d2ef1a","article-title":"Hepatic steatosis in genotype 4 chronic hepatitis C patients","author":"Khattab","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.advms.2022.12.003_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(00)80166-X","article-title":"Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3","volume":"33","author":"Rubbia-Brandt","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/437971","article-title":"Cancer incidence in Egypt: results of the national population-based cancer registry program","volume":"2014","author":"Ibrahim","year":"2014","journal-title":"J\u00a0Cancer Epidemiol"},{"key":"10.1016\/j.advms.2022.12.003_bib35","article-title":"Hepatocellular Carcinoma (HCC) in Egypt: a comprehensive overview","volume":"32","author":"Rashed","year":"2020","journal-title":"J\u00a0Egypt Natl Cancer Inst"},{"key":"10.1016\/j.advms.2022.12.003_bib36","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1099\/vir.0.82626-0","article-title":"Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma","volume":"88","author":"Abdel-Hamid","year":"2007","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.advms.2022.12.003_bib37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1440-1746.2003.03325.x","article-title":"Management of hepatitis C virus genotype 4","volume":"19","author":"Abdo","year":"2004","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib38","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.12.003_bib39","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/hep.25892","article-title":"High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials","volume":"56","author":"Marcellin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib40","first-page":"22","article-title":"Efficacy and safety of pegylated interferon \u03b1 and ribavirin in patients monoinfected with HCV genotype 4","volume":"13","author":"Kozielewicz","year":"2018","journal-title":"Przeglad Gastroenterol"},{"key":"10.1016\/j.advms.2022.12.003_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2010.110","article-title":"Insulin resistance predicts rapid virologic response to peginterferon\/ribavirin combination therapy in hepatitis C genotype 4 patients","volume":"105","author":"Khattab","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.advms.2022.12.003_bib42","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.10069","article-title":"The effect of peginterferon alpha-2a vs. Peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single centre Egyptian study","volume":"13","author":"El Raziky","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.advms.2022.12.003_bib43","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/hep.21917","article-title":"Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response","volume":"46","author":"Kamal","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.04.015","article-title":"Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response","volume":"135","author":"Ferenci","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2022.12.003_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/j.gastro.2009.10.058","article-title":"Peginterferon Alfa-2a\/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response","volume":"138","author":"Ferenci","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2022.12.003_bib46","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3748\/wjg.v22.i12.3418","article-title":"Daclatasvirvstelaprevir plus peginterferon alfa\/ribavirin for hepatitis C virus genotype 1","volume":"22","author":"Jacobson","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.advms.2022.12.003_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhep.2015.02.018","article-title":"Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders","volume":"63","author":"Jensen","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib48","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.12.003_bib49","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/apt.13923","article-title":"Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt","volume":"45","author":"Elsharkawy","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.advms.2022.12.003_bib50","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","article-title":"Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry","volume":"62","author":"Ruane","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib51","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/gutjnl-2017-315906","article-title":"Ledipasvir\/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt","volume":"68","author":"Shiha","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.advms.2022.12.003_bib52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2022.12.003_bib53","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.cgh.2017.02.020","article-title":"Real-world effectiveness and safety of oral combination antiviral therapy for hepatitis C virus genotype 4 infection","volume":"15","author":"Crespo","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","article-title":"Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir\u2013sofosbuvir (SHARED): a single-arm trial","volume":"4","author":"Gupta","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.advms.2022.12.003_bib55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2468-1253(16)30001-2","article-title":"Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial","volume":"1","author":"Asselah","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.advms.2022.12.003_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2468-1253(16)30002-4","article-title":"Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial","volume":"1","author":"Waked","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.advms.2022.12.003_bib57","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/liv.13727","article-title":"Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.advms.2022.12.003_bib58","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5114\/ceh.2020.98606","article-title":"Recommendations of the polish group of experts for HCV for the treatment of hepatitis C in 2020","volume":"6","author":"Halota","year":"2020","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib60","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.advms.2022.12.003_bib61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib62","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.12.003_bib63","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib64","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.12.003_bib65","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.12.003_bib66","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts","volume":"40","author":"Mangia","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.advms.2022.12.003_bib67","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.12.003_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100685","article-title":"The impact of COVID-19 on the cascade of care of HCV in the US and China","volume":"27","author":"Yeo","year":"2022","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib69","first-page":"117","article-title":"The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries","volume":"3","author":"Hill","year":"2017","journal-title":"J\u00a0Virus Erad"},{"key":"10.1016\/j.advms.2022.12.003_bib70","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.30342","article-title":"Highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments","volume":"69","author":"Davis","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib71","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"European association for the study of the liver. EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib72","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib73","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.30225","article-title":"Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r","volume":"69","author":"Fourati","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib74","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2022.12.003_bib75","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2022.12.003_bib76","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2022.12.003_bib77","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/jvh.13322","article-title":"Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection","volume":"27","author":"Dietz","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.advms.2022.12.003_bib78","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S2468-1253(17)30249-2","article-title":"Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030","volume":"2","author":"Sonderup","year":"2017","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.advms.2022.12.003_bib79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jvh.12668","article-title":"National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care","volume":"24","author":"El-Akel","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.advms.2022.12.003_bib80","unstructured":"http:\/\/www.hepbcppa.org\/wp-content\/uploads\/2012\/08\/Esmat-A-nation-prog-for- (accessed May 29, 2022)."},{"key":"10.1016\/j.advms.2022.12.003_bib81","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3748\/wjg.v24.i38.4330","article-title":"Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations","volume":"24","author":"Omran","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.advms.2022.12.003_bib82","unstructured":"Plan of action for the prevention n.d. http:\/\/www.emro.who.int\/images\/stories\/egypt\/VH_Plan_of_Action_FINAL_PRINT1.pdf (accessed May 29, 2022)."},{"key":"10.1016\/j.advms.2022.12.003_bib83","doi-asserted-by":"crossref","first-page":"187","DOI":"10.9745\/GHSP-D-20-00234","article-title":"Egypt's ambitious strategy to eliminate hepatitis C virus: a case study","volume":"9","author":"Hassanin","year":"2021","journal-title":"Glob Health Sci Pract"},{"key":"10.1016\/j.advms.2022.12.003_bib84","unstructured":"https:\/\/www.wipo.int\/edocs\/pubdocs\/en\/wipo_pub_gii_2019-chapter12.pdf (accessed May 29, 2022)."},{"key":"10.1016\/j.advms.2022.12.003_bib85","series-title":"Egypt's 100 Million Healthy lives campaign inspires the world","year":"2020"},{"key":"10.1016\/j.advms.2022.12.003_bib86","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and treatment program to eliminate hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112622000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112622000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:42:13Z","timestamp":1761824533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112622000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1896112622000463"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2022.12.003","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype 4 hepatitis C virus-a review of a diverse genotype","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}